Seelos therapeutics announces receipt of minutes from its end of phase ii meeting with the united states food and drug administration (fda) highlighting modifications to the primary and secondary endpoints of its phase ii study of sls-002

Company plans to continue its previously announced potential partnership discussions and expects to proceed to phase iii with sls-002 in adults with major depressive disorder (mdd) at imminent risk of suicide new york , jan. 22, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the receipt of minutes from its end of phase ii meeting with the fda.  in the meeting minutes, the fda agreed that the primary endpoint in a phase iii trial could be the change from baseline in the montgomery-Åsberg depression rating scale (madrs) total score at day 16, rather than the 24-hour timepoint that was selected in the phase ii sls-002-201 study.
SEEL Ratings Summary
SEEL Quant Ranking